Global Camrelizumab Market Strategic Research Report

Scope of the Report

The global Camrelizumab market size is predicted to grow from US$ 660 million in 2025 to US$ 1,420 million in 2032; it is expected to grow at a CAGR of 7.0% from 2026 to 2032.

Camrelizumab is a humanized anti-PD-1 monoclonal antibody. By specifically binding to the PD-1 receptor on the surface of T cells, it blocks its interaction with the ligands PD-L1 and PD-L2, relieves the suppression of immune cells in the tumor microenvironment, and restores and activates the body’s own anti-tumor immune response, thereby exerting a tumor-killing effect. As an immune checkpoint inhibitor independently developed by Hengrui Medicine, this drug features high affinity, long-lasting efficacy and controllable safety. Its approved indications widely cover liver cancer, lung cancer, esophageal cancer, nasopharyngeal cancer, cervical cancer and other tumors. It is often used in combination with chemotherapy and targeted drugs such as famitinib malate, significantly improving survival benefits for patients with advanced malignant tumors, making it one of the most widely used immunotherapeutic drugs in clinical practice in China.In 2025, global Camrelizumab production reached approximately 18.9 million units.

Camrelizumab, a humanized anti-PD-1 monoclonal antibody independently developed by Hengrui Medicine, is one of the core products in the domestic immunotherapy market. With extensive indication coverage, mature combination therapy regimens, medical insurance coverage and channel expansion to primary markets, it occupies an important position in the domestic PD-1 market. Its approved indications cover multiple high-incidence tumors including lung cancer, liver cancer, esophageal cancer, nasopharyngeal cancer and cervical cancer, making it one of the PD-1 products with the most abundant approved indications in China. In the competitive landscape, camrelizumab forms the first echelon alongside domestic PD-1 inhibitors from companies such as Innovent Biologics, BeiGene and Junshi Biosciences, consolidating its market share through advantages in medical insurance pricing, penetration in grassroots medical markets and superior data from combination therapies. With continuous volume growth driven by medical insurance, expansion of new indications and advancement in overseas markets, its market influence has been steadily rising, establishing it as a benchmark product in the field of tumor immunotherapy in China.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Camrelizumab market?

What factors are driving Camrelizumab market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Camrelizumab market opportunities vary by end market size?

How does Camrelizumab break out by Type, by Application?

This report presents a comprehensive overview of the global Camrelizumab market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 200mg / Vial
• 100mg / Vial

Segment by Antibody Type

• Monoclonal Antibody
• Polyclonal Antibody

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Application

• Lung Cancer
• Liver Cancer
• Esophageal Cancer
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Camrelizumab market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Lung Cancer, Liver Cancer, Esophageal Cancer evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact